𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets

✍ Scribed by Louisa Clare Johnston; Michael John Jackson; Sarah Rose; Andrew Christopher McCreary; Peter Jenner


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
286 KB
Volume
25
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Long‐acting full dopamine D~2~ agonists produce less dyskinesia in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated primates and in Parkinson's disease than effective antiparkinsonian doses of levodopa. They do not however, prevent priming for dyskinesia expression on subsequent levodopa exposure. In contrast, the effects of partial D~2~ receptor agonists on dyskinesia are unclear. We now examine the ability of the partial D~2~ agonist pardoprunox (SLV308) to improve motor function and its propensity to prime for dyskinesia in drug naïve, MPTP‐treated common marmosets. Previously, drug naïve, MPTP‐treated common marmosets were treated with equivalent doses of either pardoprunox (SLV308) (0.1 mg/kg po), ropinirole (0.18 mg/kg po), or levodopa (10 mg/kg po BID) for 28 days. All treatments induced a similar reduction of motor disability. Dyskinesia induced by levodopa was of greater intensity than that following administration of either pardoprunox (SLV308) or ropinirole. Administration of pardoprunox (SLV308) resulted in dyskinesia that was less intense and of shorter duration than either ropinirole or levodopa. At the end of drug treatment, acute challenge with levodopa resulted in the expression of marked dyskinesia in animals that had previously received chronic levodopa or ropinirole treatment. However, animals previously treated with pardoprunox (SLV308) showed only mild dyskinesia in response to the levodopa challenge. These results suggest that the partial D~2~ agonist pardoprunox (SLV308) is less likely to prime for dyskinesia or to lead to the expression of dyskinesia than either levodopa or full dopamine agonists. © 2010 Movement Disorder Society


📜 SIMILAR VOLUMES


Pramipexole combined with levodopa impro
✍ Kayhan A. Tayarani-Binazir; Michael J. Jackson; Sarah Rose; C. Warren Olanow; Pe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

## Abstract Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining